Boc-cyclopropyl Alanine | 900802-61-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-cyclopropyl Alanine
• 英文别名: (S)-2-(tert-butoxycarbonyl-cyclopropyl-amino)-propionic acid；N-Boc-cyclopropylalanine；(S)-2-((tert-Butoxycarbonyl)(cyclopropyl)amino)propanoic acid；(2S)-2-[cyclopropyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid
• CAS: 900802-61-1
• 化学式: C₁₁H₁₉NO₄
• 分子量: 229.276
• InChiKey: MXFDTAAFXOYLGV-ZETCQYMHSA-N

物化性质

• 沸点：
  338.6±21.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Boc-cyclopropylalanine p-nitrobenzyl ester 在 sodium hydroxide 、 sodium chloride 作用下， 以 甲醇 、 水 、 柠檬酸 为溶剂， 生成 Boc-cyclopropyl Alanine
  参考文献：
  名称：

  Synthesis of cyclopropane amino acids

  摘要：

  本发明公开了含有至少一种环丙基氨基酸的环丙烷（“环丙基”）氨基酸和肽。本发明还公开了合成含有至少一种环丙基氨基酸的环丙烷氨基酸和肽的方法。环丙基氨基酸可用作酶抑制剂，并可用作肽激素中天然氨基酸的替代物，以增强生物活性，将其稳定到包含它的肽中，以避免被酶水解，并将这些肽转化为酶抑制剂。

  公开号：

  US04629784A1

文献信息

• Protease inhibitors
  申请人：——

  公开号：US20020049316A1

  公开（公告）日：2002-04-25

  The present invention provides compounds of formula (I) which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy; and metabolic bone disease therewith.

  本发明提供了一种公式（I）的化合物，其抑制蛋白酶，包括卡特普辛K，以及这些化合物的药物组合物，以及治疗骨量过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说是骨关节炎和类风湿关节炎；帕吉特病；高钙血症或恶性肿瘤；以及代谢性骨病。
• Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof
  申请人：SUNSHINE LAKE PHARMA CO., LTD

  公开号：US20150079028A1

  公开（公告）日：2015-03-19

  Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

  提供了一种具有公式(I)的化合物，或其立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂化物、代谢物、药用盐或前药，可用于治疗HCV感染或HCV疾病。还提供了包含本处所述化合物的药物组合物，可用于治疗HCV感染或HCV疾病。
• Macrocyclic Compounds and Compositions Useful as Bace Inhibitors
  申请人：Lerchner Andreas

  公开号：US20080214526A1

  公开（公告）日：2008-09-04

  The invention relates to novel macrocyclic compounds of the formula in which R 1 , R 3 , V 1 , V 2 , X 1 , X 2 , Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 or 18, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

  本发明涉及新型大环化合物的公式，其中R1、R3、V1、V2、X1、X2、Y、Z、Ar、AA和n如规范中所定义，大环环中包含的环原子数为14、15、16、17或18，在自由碱形式或酸盐形式下，它们的制备，它们作为药物的用途以及包含它们的药物。
• Pyrrolidin-3-Yl Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
  申请人：Coburn Craig A.

  公开号：US20080287523A1

  公开（公告）日：2008-11-20

  The present invention is directed to pyrrolidin-3-yl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及吡咯烷基衍生物化合物，它们是β-分泌酶酶的抑制剂，并且在治疗涉及β-分泌酶酶的疾病，如阿尔茨海默病方面有用。本发明还涉及包含这些化合物的制药组合物，以及在治疗涉及β-分泌酶酶的疾病中使用这些化合物和组合物。
• Macrocyclic compounds and compositions useful as BACE inhibitors
  申请人：Novartis AG

  公开号：US08008250B2

  公开（公告）日：2011-08-30

  Macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 or 18, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them are presented.

  本发明提供了式子中R1、R3、V1、V2、X1、X2、Y、Z、Ar、AA和n的定义如规范所述的大环化合物，所述大环中包括14、15、16、17或18个环原子，以自由碱形式或酸加成盐形式存在，以及它们的制备方法、用作药物的方法和包括它们的药物。